Literature DB >> 28032546

Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the Milan criteria after hepatectomy.

Jun-Yi Shen1, Chuan Li1, Tian-Fu Wen2, Lv-Nan Yan1, Bo Li1, Wen-Tao Wang1, Jia-Yin Yang1, Ming-Qing Xu1.   

Abstract

BACKGROUND: Assessing the outcomes of surgeries for hepatocellular carcinoma (HCC) patients who exceed the Milan criteria is necessary. Some studies have demonstrated that preoperative or postoperative alpha fetoprotein (AFP) can predict HCC patients' prognoses.
METHODS: A total of 280 HCC patients who were positive for AFP and received curative resection were retrospectively analyzed. The patients were classified into three groups according to their preoperative and postoperative AFP levels (group A: normalized AFP; group B: AFP decreases >50%, but continued abnormality; and group C: AFP decreases <50%). Disease-free survival and overall survival rates were analyzed using the Kaplan-Meier method. The factors associated with AFP changes were evaluated by logistic regression.
RESULTS: AFP dynamic changes were independently associated with disease-free survival and overall survival rates. Group A had better 3- and 5-y survivals than groups B or C (58.7% and 39.5% versus 31.3% and 14.9% versus 17.1% and 8.8%, P < 0.001). Preoperative AFP, tumor differentiation, tumor diameter, microvascular invasion, and satellite nodules remained significant risk factors that were associated with AFP changes. Furthermore, in group A, the disappearances of AFP within and beyond 8 wk resulted in similar overall survival rates (P > 0.05). Among those with HCC recurrence, the patients treated with resurgery or radiofrequency ablation achieved the best recurrence to death survivals. Those treated with transcatheter arterial chemoembolization achieved the next best survivals.
CONCLUSIONS: AFP changes predicted the prognoses of patients with HCC beyond the predictions of the Milan criteria. Preoperative AFP (>400 ng/mL), tumor differentiation, tumor diameter, and satellite nodules were the risk factors related to AFP normalization. The regular follow-up and early detection of recurrent HCCs that are suitable for curative therapies, such as resurgery and radiofrequency ablation, might improve the prognoses. Other therapies, such as transcatheter arterial chemoembolization, might also be effective.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AFP change; HCC; Hepatectomy; Milan criteria; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 28032546     DOI: 10.1016/j.jss.2016.10.005

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  16 in total

Review 1.  Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus.

Authors:  Tianfu Wen; Chen Jin; Antonio Facciorusso; Matteo Donadon; Ho-Seong Han; Yilei Mao; Chaoliu Dai; Shuqun Cheng; Bixiang Zhang; Baogang Peng; Shunda Du; Changjun Jia; Feng Xu; Jie Shi; Juxian Sun; Peng Zhu; Satoshi Nara; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

2.  A Panel of Genes Identified as Targets for 8q24.13-24.3 Gain Contributing to Unfavorable Overall Survival in Patients with Hepatocellular Carcinoma.

Authors:  Kun Zhao; Yu Zhao; Jia-Yi Zhu; Hui Dong; Wen-Ming Cong; Yi Yu; Hui Wang; Zhong-Zheng Zhu; Qing Xu
Journal:  Curr Med Sci       Date:  2018-08-20

3.  Preoperative MRI features and clinical laboratory indicators for predicting the early therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization combined with High-intensity focused ultrasound treatment.

Authors:  Haiping Zhang; Xiaojing He; Jiayi Yu; Wenlong Song; Xinjie Liu; Yangyang Liu; Jun Zhou; Dajing Guo
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

4.  Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection.

Authors:  Narongsak Rungsakulkij; Wikran Suragul; Somkit Mingphruedhi; Pongsatorn Tangtawee; Paramin Muangkaew; Suraida Aeesoa
Journal:  World J Clin Cases       Date:  2018-06-16       Impact factor: 1.337

5.  A novel molecular-clinicopathologic nomogram to improve prognosis prediction of hepatocellular carcinoma.

Authors:  Zhongjing Zhang; Wanqing Weng; Weiguo Huang; Boda Wu; Yi Zhou; Jie Zhang; Tuo Deng; Wen Ye; Jiecheng Zhang; Jianyang Ao; Qiyu Zhang; Keqing Shi
Journal:  Aging (Albany NY)       Date:  2020-06-30       Impact factor: 5.682

6.  A Nomogram Predicting Extrahepatic Metastases for Patients with Adjuvant Transarterial Chemoembolization after Hepatectomy.

Authors:  Shipeng Chen; Yuzhen Gao; Zheng Li; Jian'an Jia; Meng Fang; Mengmeng Wang; Huijuan Feng; Qinjunjie Chen; Wenqian Guan; Ziyi Wang; Chunfang Gao
Journal:  J Cancer       Date:  2018-10-20       Impact factor: 4.207

7.  Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection.

Authors:  Narongsak Rungsakulkij; Wikran Suragul; Somkit Mingphruedhi; Pongsatorn Tangtawee; Paramin Muangkaew; Suraida Aeesoa
Journal:  Infect Agent Cancer       Date:  2018-06-08       Impact factor: 2.965

Review 8.  Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence.

Authors:  Alessandra Mangia; Davide Bellini; Umberto Cillo; Andrea Laghi; Giuseppe Pelle; Vanna Maria Valori; Eugenio Caturelli
Journal:  BMC Gastroenterol       Date:  2020-08-03       Impact factor: 3.067

9.  Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: A meta-analysis.

Authors:  Chao He; Wei Peng; Xiaojuan Liu; Chuan Li; Xueting Li; Tian-Fu Wen
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

10.  Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization.

Authors:  Chao He; Xiaoyun Zhang; Chuan Li; Wei Peng; Tian-Fu Wen; Lv-Nan Yan; Jiayin Yang; Wusheng Lu
Journal:  Oncotarget       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.